Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Audrey Vincent

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0058-2058; OpenAlex author ID A5050382962. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 11

  1. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Last author DOI 10.1111/boc.202100003↗
  2. Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival. Co-author DOI 10.3390/cancers12113309↗
  3. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Co-author DOI 10.1002/mc.23090↗
  4. Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Co-author DOI 10.18632/oncotarget.9009↗
  5. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling … Co-author DOI 10.1016/j.bbagrm.2015.10.014↗
  6. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Co-author DOI 10.1038/onc.2014.11↗
  7. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-re… Co-author DOI 10.18632/oncotarget.3414↗
  8. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-12-1075↗
  9. Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2'-deoxycytidine. Co-author DOI 10.1371/journal.pone.0043456↗
  10. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(10)62307-0↗
  11. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-10-3431↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabelle VAN SEUNINGEN · 6 shared papers, 2015–2022 · strength 0.46
  2. Nicolas Jonckheere · 5 shared papers, 2015–2022 · strength 0.38
  3. Elsa Hadj Bachir · 2 shared papers, 2020–2022 · strength 0.22
  4. Stéphanie Truant · 2 shared papers, 2019–2022 · strength 0.20
  5. Romain Vasseur · 3 shared papers, 2015–2019 · strength 0.19
  6. Michael Goggins · 5 shared papers, 2011–2016 · strength 0.18
  7. Noriyuki Omura · 4 shared papers, 2011–2016 · strength 0.15
  8. Seung‐Mo Hong · 4 shared papers, 2011–2016 · strength 0.15
  9. Fatima Lahdaoui · 2 shared papers, 2015–2019 · strength 0.13
  10. Charles Poiraud · 1 shared paper, 2022 · strength 0.12
  11. Nicolas Stoup · 1 shared paper, 2022 · strength 0.12
  12. Pascal Pigny · 1 shared paper, 2022 · strength 0.12
  13. Nicolas Skrypek · 2 shared papers, 2015 · strength 0.11
  14. Nihad Boukrout · 1 shared paper, 2020 · strength 0.11
  15. Julie Auwercx · 1 shared paper, 2020 · strength 0.11
  16. Mathieu Gautier · 1 shared paper, 2020 · strength 0.11
  17. Mitsuro Kanda · 2 shared papers, 2012–2016 · strength 0.08
  18. Mehdi El Amrani · 1 shared paper, 2019 · strength 0.08
  19. Ralph H. Hruban MD · 2 shared papers, 2011–2012 · strength 0.06
  20. Michael Ayars · 1 shared paper, 2016 · strength 0.05
  21. Masamichi Mizuma · 1 shared paper, 2016 · strength 0.05
  22. Anirban Maitra · 1 shared paper, 2016 · strength 0.05
  23. Yannick Delpu · 1 shared paper, 2015 · strength 0.05
  24. Jérôme Torrisani · 1 shared paper, 2015 · strength 0.05
  25. Joseph M. Herman · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.